trial · primary record
Doravirine
Human Immunodeficiency Virus (HIV) Infection
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 84 |
| Primary completion | 2034-04-11 |
| Primary endpoint | Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Postdose (AUC0-24hr) of Doravirine (DOR) Following Once-Daily Dosing in Plasma at Steady-State |
| Registry ID | NCT04375800 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:46.083Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04375800
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.